Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

The FDA is set to request Sarepta Therapeutics to halt shipments of its gene therapy, Elevidys, after a third patient's death ...

Investor Action Deadline If you purchased Sarepta securities during the Class Period and suffered losses, you have until August 25, 2025, to request the Court appoint you as lead plaintiff.

Health Care FDA Layoffs Could Compromise Safety of Medications Made at Foreign Factories, Inspectors Say Beyond staff cuts, the departures of some longtime investigators in recent months have left ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previo ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently provided updates that may have influenced its stock performance. The announcement of a safety update for ELEVIDYS, concerning severe side effects and ...

Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta’s most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy.

NEW YORK – In a safety communication earlier this week, the US Food and Drug Administration said it is investigating the risk of fatal acute liver failure with Sarepta Therapeutics' Elevidys ...